| Amyotrophic Lateral Sclerosis
Radicava vs Tiglutik
Side-by-side clinical, coverage, and cost comparison for amyotrophic lateral sclerosis.Deep comparison between: Radicava vs Tiglutik with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTiglutik has a higher rate of injection site reactions vs Radicava based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tiglutik but not Radicava, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Radicava
Tiglutik
At A Glance
IV infusion or Oral
Daily (cyclic dosing schedule)
Oral
Every 12 hours
Benzothiazole
Indications
- Amyotrophic Lateral Sclerosis
- Amyotrophic Lateral Sclerosis
Dosing
Amyotrophic Lateral Sclerosis RADICAVA 60 mg IV infusion over 60 minutes or RADICAVA ORS 105 mg (5 mL) orally/via feeding tube in the morning after overnight fasting; initial cycle: daily for 14 days then 14-day drug-free period; subsequent cycles: daily for 10 days out of 14-day periods then 14-day drug-free periods.
Amyotrophic Lateral Sclerosis 50 mg (10 mL) orally or via PEG-tube twice daily every 12 hours, taken at least 1 hour before or 2 hours after a meal.
Contraindications
- History of hypersensitivity to edaravone or any inactive ingredient in this product
- History of severe hypersensitivity reactions to riluzole or to any of its components (anaphylaxis has occurred)
Adverse Reactions
Most common (>=2%) contusion, gait disturbance, headache, dermatitis, eczema, respiratory failure/disorder/hypoxia, glycosuria, tinea infection
Serious hypersensitivity reactions, sulfite allergic reactions
Postmarketing hypersensitivity reactions, anaphylaxis
Most common (>=5%) Asthenia, nausea, decreased lung function, hypertension, abdominal pain
Serious Hepatic injury, neutropenia, interstitial lung disease
Postmarketing Acute hepatitis, icteric toxic hepatitis, renal tubular impairment, pancreatitis
Pharmacology
Edaravone is a substituted 2-pyrazolin-5-one whose therapeutic mechanism in ALS is unknown. At exposures at least 5 times the recommended dose, edaravone does not prolong the QT interval to any clinically relevant extent.
The mechanism by which riluzole exerts its therapeutic effects in patients with ALS is unknown; its clinical pharmacodynamics have not been determined in humans.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Radicava
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (0/12)
Tiglutik
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Radicava
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tiglutik
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Radicava
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Tiglutik
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Radicava.
$50/fillfill
Tiglutik Co-pay SupportCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RadicavaView full Radicava profile
TiglutikView full Tiglutik profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.